Director Fromkin sold 221,951 shares (222.0K) for $7,438,111.20 in 2 transactions on 5/28, cutting holdings 74.9%
Andrew J. Fromkin, a Director at Immunovant, executed 2 separate sales on 2026-05-28, totaling 221,951 shares for $7,438,111.20 at a blended average price of $33.51. This transaction reduced his direct holdings from 296,333 shares to 74,382 shares, representing a 74.9% reduction in his non-derivative position. The company reported net income of $-110,635,000.00 for its most recent fiscal year and carries a market cap of $6,834,733,846.93. The stock is currently trading at $33.29, up 23.5% over 30 days and 20.0% over 90 days, though it remains 8.2% below its 52-week high of $36.28. The substantial scale of this divestiture—involving over $7.4M in proceeds—reflects a material reduction in the director's direct equity stake at an unprofitable company during a period of positive momentum in the stock price.